<i>In Vivo</i> panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA®) Anti-CD20 CAR
Juliet Crabtree(Unknown), Robert Mabry, Ian Langer, Scott Barros(Alnylam Pharmaceuticals (United States)), Allen Horhota, Jui Dutta-Simmons, Prapti Vyas, Akinola Olumide Emmanuel(University of Chicago), Muthusamy Jayaraman(Forma Therapeutics (United States)), Isin Dalkilic-Liddle(Forma Therapeutics (United States)), Tracy L. DiMezzo, Akshi Thakkar, Megan D. Hoban(Fate Therapeutics (United States)), David Soto, Grace Chen(University of Michigan), LT Thiruneelakantapillai, Ganapathy Subramanian Sankaran, Maja Sedic(Forma Therapeutics (United States)), Karolina Kosakowska(Forma Therapeutics (United States)), Frank Neumann(Forma Therapeutics (United States))
Cited by 4
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
|Nature Biotechnology|2008|1.2k